Human CD20 Antibody Family

Anti-hCD20 comparative table | InvivoGen

InvivoGen's anti-hCD20 isotype family features the variable region of either Rituximab, Ofatumumab, or Obinutuzumab clinical monoclonal antibodies (mAbs), which all target the human CD20 antigen (hCD20).
Our anti-hCD20 antibodies feature either native or engineered constant regions (Fc), which results in different capacities to exert biological functions such as complement-dependent cytotoxicity (CDC), antibody-dependent cellular cytotoxicity (ADCC), or apoptosis.

  • Rituximab is a type I (first generation) mouse/human chimeric IgG1 mAb.
  • Ofatumumab is a type I (first generation) fully human IgG1 mAb.
  • Obinutuzumab is a type II (second generation) non-fucosylated, fully humanized IgG1 mAb.

InvivoGen's anti-hCD20 antibodies are generated by recombinant DNA technology, produced in CHO cells, and purified by affinity chromatography according to their isotype (protein G for IgG peptide M for IgA, and protein L for IgE/IgM).

The CD20 antigen is a transmembrane phosphoprotein that is expressed on the surface of both resting and activated B lymphocytes, but it is lost upon differentiation into plasma cells. Therefore a useful marker of B-cell lymphomas, as demonstrated in both humans and dogs.
Anti-human CD20 monoclonal antibodies (rituximab, ofatumumab, and obinutuzumab) have been approved by the FDA to treat B-cell non-Hodgkin's lymphoma or chronic lymphocytic leukemia (CLL). 

More isotypes are available and can be used for comparison of biological activities such as ADCC (see below or in the 'upon request' section).

Customer Service
& Technical Support
Contact us
Shopping cart is empty